Exelixis (EXEL) Accumulated Expenses (2010 - 2026)
Exelixis (EXEL) posted quarterly Accumulated Expenses of $87.5 million for Q2 2026, down 2.49% year-over-year from $89.7 million in Q2 2025, and down 14.39% quarter-over-quarter from $102.2 million in Q1 2026.
Analysis
Exelixis (EXEL) Accumulated Expenses (2010 - 2026) Analysis & Trends
Exelixis' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $87.5 million for Q2 2026.
- In Q2 2026, Accumulated Expenses fell 2.49% year-over-year to $87.5 million; the TTM figure through Apr 2026 stood at $87.5 million (down 2.49% YoY), while the FY2026 annual figure was $102.2 million, down 6.93% from the prior year.
- Accumulated Expenses for Q2 2026 stood at $87.5 million, down from $102.2 million in the prior quarter.
- The five-year high for Accumulated Expenses was $109.8 million in Q1 2025, with the low at $42.8 million in Q2 2022.
- The 5-year median for Accumulated Expenses is $77.2 million (2022), against an average of $79.4 million.
- The sharpest annual moves came in 2023 and 2026: Accumulated Expenses surged 32.23% in 2023, then dropped 6.93% in 2026.
- Exelixis' Accumulated Expenses stood at $77.2 million in 2022, then increased by 20.95% to $93.3 million in 2023, then declined by 2.91% to $90.6 million in 2024, then grew by 15.19% to $104.4 million in 2025, then slipped by 16.15% to $87.5 million in 2026.
- Business Quant data shows EXEL's Accumulated Expenses at $87.5 million in Q2 2026, $102.2 million in Q1 2026, and $104.4 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 68.63 Mn |
| Apr 3, 2026 | 87.51 Mn |
| Jan 2, 2026 | 102.22 Mn |
| Oct 3, 2025 | 104.36 Mn |
| Jul 4, 2025 | 72.25 Mn |
| Apr 4, 2025 | 89.75 Mn |
| Jan 3, 2025 | 109.83 Mn |
| Sep 27, 2024 | 90.61 Mn |
| Jun 28, 2024 | 71.81 Mn |
| Mar 29, 2024 | 72.96 Mn |
| Dec 29, 2023 | 93.33 Mn |
| Sep 29, 2023 | 81.40 Mn |
| Jun 30, 2023 | 68.21 Mn |
| Mar 31, 2023 | 56.55 Mn |
| Dec 30, 2022 | 77.16 Mn |
| Sep 30, 2022 | 66.93 Mn |
| Jul 1, 2022 | 61.45 Mn |
| Apr 1, 2022 | 42.77 Mn |
| Dec 31, 2021 | 61.97 Mn |
| Oct 1, 2021 | 53.31 Mn |